Financial Summary (All financials)
| In millions, except per share items | May-31-22 | May-31-21 | May-31-20 | May-31-19 | May-31-18 | May-31-17 | May-31-16 | May-31-15 |
| Revenues | 46,710.0 | 44,538.0 | 37,403.0 | 39,117.0 | 36,397.0 | 34,350.0 | 32,376.0 | 30,601.0 |
| Revenue growth | 4.9% | 19.1% | -4.4% | 7.5% | 6.0% | 6.1% | 5.8% | 10.1% |
| Cost of goods sold | 25,231.0 | 24,576.0 | 21,162.0 | 21,643.0 | 20,441.0 | 19,038.0 | 17,405.0 | 16,534.0 |
| Gross profit | 21,479.0 | 19,962.0 | 16,241.0 | 17,474.0 | 15,956.0 | 15,312.0 | 14,971.0 | 14,067.0 |
| Gross margin | 46.0% | 44.8% | 43.4% | 44.7% | 43.8% | 44.6% | 46.2% | 46.0% |
| Selling, general and administrative | | | | | | | | |
| Sales and marketing | 3,850.0 | 3,114.0 | 3,592.0 | 3,753.0 | 3,577.0 | 3,341.0 | 3,278.0 | 3,213.0 |
| General and administrative | 10,954.0 | 9,911.0 | 9,534.0 | 8,949.0 | 7,934.0 | 7,222.0 | 7,191.0 | 6,679.0 |
| EBITA | 6,265.0 | 6,413.0 | 2,937.0 | 4,674.0 | 4,337.0 | 4,641.0 | 4,477.0 | 4,162.0 |
| EBITA margin | 13.4% | 14.4% | 7.9% | 11.9% | 11.9% | 13.5% | 13.8% | 13.6% |
| Amortization of intangibles | | | | | | 10.0 | 13.0 | 43.0 |
| EBIT | 6,265.0 | 6,413.0 | 2,937.0 | 4,674.0 | 4,337.0 | 4,631.0 | 4,464.0 | 4,119.0 |
| EBIT margin | 13.4% | 14.4% | 7.9% | 11.9% | 11.9% | 13.5% | 13.8% | 13.5% |
| Pre-tax income | 6,651.0 | 6,661.0 | 2,887.0 | 4,801.0 | 4,325.0 | 4,886.0 | 4,623.0 | 4,205.0 |
| Income taxes | 605.0 | 934.0 | 348.0 | 772.0 | 2,392.0 | 646.0 | 863.0 | 932.0 |
| Tax rate | 9.1% | 14.0% | 12.1% | 16.1% | 55.3% | 13.2% | 18.7% | 22.2% |
| Net income | 6,046.0 | 5,727.0 | 2,539.0 | 4,029.0 | 1,933.0 | 4,240.0 | 3,760.0 | 3,273.0 |
| Net margin | 12.9% | 12.9% | 6.8% | 10.3% | 5.3% | 12.3% | 11.6% | 10.7% |
| |
| Diluted EPS | $3.75 | $3.56 | $1.60 | $2.49 | $1.17 | $2.51 | $2.16 | $1.85 |
| Shares outstanding (diluted) | 1,610.8 | 1,609.4 | 1,591.6 | 1,618.4 | 1,659.1 | 1,692.0 | 1,742.5 | 1,768.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|